Asia-Pacific Psychiatry Therapies Market

Asia-Pacific Psychiatry Therapies Market Size (2024 to 2029)

The size of the psychiatry therapies market in the Asia-Pacific is anticipated to witness a CAGR of 9.16% from 2024 to 2029.

Psychiatry is a branch of medicine that deals with mental illnesses and treats them through pharmaceutical therapy.

In addition to drug therapy, psychiatrists use several psychosocial treatments to help patients. The modern Asian Pacific population is increasingly focused on work and life outside of themselves. As a result, people have more mental health problems than ever before, and self-care is neglected.The increase in the frequency of mental diseases, the rise in the geriatric population, and the expansion of mental health awareness programs are a few factors accelerating the psychiatry therapies market in the APAC region. Furthermore, the mental health market is rising due to increased awareness of mental diseases due to education and campaigning for tremendous respect for human rights and less stigma.

According to the World Health Organization, mental illness affects one out of every four people. Given the growth in work pressure in the Asia Pacific, this trend is expected to continue. People are devoting less time to themselves, thus affecting their mental health. Mental treatment should be sought out more regularly in the future, given the expanding needs of the Asia Pacific workforce.Individuals with poor mental health are at risk due to the pandemic, which includes an increase in mental illness, disruption of treatment, medications, and lifeline support services, as well as a negative impact on the market. In addition, a shortage of competent experts in rural areas, increased public health awareness, healthcare infrastructure, and an increase in the number of patients with fewer medical facilities are all further estimated to be limiting the market.

This research report on the Asia-Pacific psychiatry therapies market has been segmented and sub-segmented into the following categories

Asia-Pacific Psychiatry Therapies Market - By Psychology Type

• Social Psychology
• Abnormal Psychology
• Biological Psychology
• Others

Asia-Pacific Psychiatry Therapies Market - By Type of Medication

• Antidepressants
• Antipsychotics
• Depressants
• Anxiolytics
• Mood Stabilisers
• Stimulants
• Others

Asia-Pacific Psychiatry Therapies Market - By Type of Therapy

• Counseling
• Cognitive Behavioural Therapy
• Family Therapy
• Psychotherapy
• Group Therapy
• Relationship Counselling
• Interpersonal Therapy
• Behavioral Activation
• Others

Asia-Pacific Psychiatry Therapies Market - By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, Asia Pacific has the third-largest market for psychiatry therapy globally by share. It is also the fastest-growing region globally, owing to factors such as rising awareness about mental health and changing lifestyles. In addition, factors such as the growing prevalence of psychological ailments and stress levels are expected to result in the growth of this market.

Asia Pacific countries are predicted to develop at the fastest rate in this market as people become more conscious of the importance of mental health.

Regional governments are also in charge of large-scale healthcare provision for their citizens. In the future, these locations are expected to provide psychiatric counseling, among other services.Furthermore, specific countries, such as India and China, are investing in cutting-edge technology and telecommunications and hiring more mental health specialists. As a result, it will positively impact the foreseeable future.Regionally, countries like India and China are growing in income, and many product-based businesses are developing health practices. Because of the rise in patients, healthcare professionals and corporate employees are affected. Furthermore, an increase in mental health activities in the healthcare sector to produce novel services and the existence of key players operating in the region contribute to the market's regional expansion.

KEY MARKET PLAYERS

Companies playing a pivotal role in the Asia Pacific psychiatry therapies market are AstraZeneca, Universal Health Services Inc., Johnson & Johnson, Pfizer, GlaxoSmithKline, Eli Lilly, Bristol-Meyer Squibb, Wyeth, Astellas Pharma Inc., and others.